Research article · 12 Jun 2025
Conference abstractPublished 2017
Adjuvant combinations in protein-based nanocapsules induce superadditive stimulation of dendritic cells, and highly effective T cell responses
Max Planck Institute for Polymer Research, Germany Johannes Gutenberg-University, Mainz, Germany University Medical Center, Mainz, Germany
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
One aspect of vaccine development is to combine distinctly acting adjuvants to archive superadditive effects on immune cell activation. Moreover, a functional vaccine also requires an antigen source to enable the induction of T cell responses via antigenpresenting cells, particularly Dendritic Cells (DC), which are capable to activate even naive T cells. A promising approach to meet this challenge is the application of nanoparticles as a drug-delivery-system. In a first initial step, we analyzed and compared the immunostimulatory potential of different soluble TLR and NLR ligand combinations. We identified resiquimod (R848, specific for TLR7 and muramyldipeptide (MDP, specific for NOD2) as a superadditive stimulatory adjuvant combination. Particulated in spermine-modified dextran-nanoparticles, the combination R848+MDP stimulate murine Bone Marrow-Derived Dendritic Cells (BMDC) stronger than the soluble adjuvant application. The second step was to combine adjuvants and antigen in one nanocarrier. For this purpose, we encapsulated the experimentally evaluated adjuvant combination (R848+MDP) in well-characterized polymeric nanocapsules, whose shell consists of cross-linked ovalbumin (OVA) protein. OVA is a commonly used model antigen. To assess the capsules’ immunostimulatory potential, we treated BMDC with the adjuvant-loaded nanoparticles. The expression of the surface activation markers CD80/CD86 and the secretion of proinflammatory cytokines were measured by flow cytometry and cytometric bead array, respectively. The capability of the adjuvant-loaded OVA-nanocapsules to mediate OVA-specific T cell responses was assessed by performing T cell proliferation assays with transgenic OT-I (CD8+) and OT-II (CD4+) T cells that recognize OVAderived antigens. Our data showed that particulated co-delivery of R848 and MDP activates murine BMDC in a superadditive manner as compared with single-delivery of the adjuvants. Additionally, the application of R848+MDP via OVA-nanocapsules evoked a strong antigen-specific T cell proliferation. These results show that R848/MDP-loaded OVA-nanocapsules are highly active to induce superior antigen-specific T cell responses.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Pharmaceutics & Drug Delivery Research.
Research article · 20 Feb 2025
Sustained Drug Delivery in Pharmaceutical Dosage Forms for Novel Approaches of Formulation Design
Research article · 23 Jan 2025
Cutting Out Counterfeits: How Blockchain Can Revolutionize Drug Traceability?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutics & Drug Delivery Research
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “David Passlick”
- BylineArticles whose byline prints “Keti Piradashvili”
- BylineArticles whose byline prints “Denise Bamberger”
- BylineArticles whose byline prints “Peter Wich”
- BylineArticles whose byline prints “Matthias Bros”
- BylineArticles whose byline prints “Stephan Grabbe”
- BylineArticles whose byline prints “Katharina Landfester”
- BylineArticles whose byline prints “Volker Mailaender”
